Central America Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Central America Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Central America Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Legislative and regulatory improvements to the Central American healthcare system will further strengthen sector coordination, enhancing medical efficiencies and treatments over the long-term. The region's ageing population and dependence on pharmaceutical imports will increase foreign investment appeal as public health provision grows.

Headline Expenditure Projections

  • Pharmaceuticals: USD3.7bn in 2014 to USD3.9bn in 2015; +4.6%. Our forecast has been maintained since Q 1 15 .

  • Healthcare: USD16.5bn in 2014 to USD17.4bn in 2015; +4.9%. Our forecast has been revised down wards since Q 4 15 due to revised macroeconomic data.

Risk/Reward Index

Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q116 Pharmaceutical Risk/Reward Index (RRI), the Americas scores 49 out of 100, below Western Europe (67), Asia Pacific (52), and Central and Eastern Europe (49), but above the Middle East and Africa (40.3). Of the six Central American countries surveyed Panama's RRI score ranks first at 44.0, followed by Costa Rica (43.2), Guatemala (38.8), Nicaragua (34.3), El Salvador 33.8 and Honduras (33.4). The main factor bringing down the Americas score lies with its underdeveloped regulatory and patent regimes and poor clinical data protection.

Latest Updates

October 2015

  • Bayer invested USD1.7mn to modernise its plant in Ilopango, El Salvador. The funds were used in technology upgrades, and remodeling and updating of software infrastructure.

September 2015

  • The Brazilian government donated a cache of second generation antiretroviral drugs to the El Salvador government under a bilateral cooperation initiative for the prevention and control of HIV infection.

  • Panama's Health Ministry provided a contribution of USD640,774 to the UN Development Programme (UNDP).

August 2015

  • The Costa Rican government established the National Health Policy, in an effort to improve public health services and promote unified healthcare. While Costa Rica's public health system already utilises universal medical care, the new policy is meant to 'address major challenges and further unify actions within the health field' according to the Ministry of Health.

  • The Honduran government established a new health advisory committee with the aim of improving the healthcare sector's regulatory environment. The committee will contribute to regulatory reforms, promotions and the general monitoring of the industry to ensure the availability of safe and effective healthcare services to citizens.

  • The Panamanian government announced the installation of a new Committee on Labour, Health and Social Development, known informally in the Ministry of Health as simply the Health Committee.

BMI Economic View

The region's economic trajectory remains divergent. Panama will continue to be the regional outperformer, boasting the strongest economy of Central America, excluding Mexico. Countries like Costa Rica and Guatemala, who previously suffered from struggling economies, will begin to see financial improvements in 2015 through strong investment, an uptake in private consumption, and national savings through tax reform. El Salvador will also see mild economic improvements as heightened consumption drives economic growth. Guatemala and Honduras will remain in weak economic positions, with expectations for little investment opportunities.

BMI Political View

Regional corruption and security risks continue to pose threats to Central America. Drug cartels, counterfeit products, heightened crime, and violence will remain major concerns to Central American political stability. Social unrest in Honduras and Nicaragua will be particularly problematic in 2015 as the political landscape of these countries becomes threatened through accusations of government corruption and poor business environments.

BMI Industry View
7
SWOT
9
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Central America Pharmaceutical Sales, Historic Data And Forecasts
12
Guatemala
12
Table: Guatemala Pharmaceutical Sales Forecasts
12
Costa Rica
12
Table: Costa Rica Pharmaceutical Sales Forecasts
13
El Salvador
13
Table: El Salvador Pharmaceutical Sales Forecasts
13
Honduras
13
Table: Honduras Pharmaceutical Sales Forecasts
14
Panama
14
Table: Panama Pharmaceutical Sales Forecasts
14
Nicaragua
14
Table: Nicaragua Pharmaceutical Sales Forecasts
15
Healthcare Market Forecast
16
Table: Central America Healthcare Expenditure Trends, Historical Data And Forecasts
18
Guatemala
18
Table: Guatemala Healthcare Expenditure Forecasts
18
Costa Rica
19
Table: Costa Rica Healthcare Expenditure Forecasts
19
El Salvador
19
Table: El Salvador Healthcare Expenditure Forecasts
19
Panama
20
Table: Panama Healthcare Expenditure Forecasts
20
Honduras
20
Table: Honduras Healthcare Expenditure Forecasts
21
Nicaragua
21
Table: Nicaragua Healthcare Expenditure Forecasts
21
Pharmaceutical Trade Forecast
22
Guatemala
24
Table: Guatemala Pharmaceutical Trade Data And Forecasts (USDmn)
24
Costa Rica
24
Table: Costa Rica Pharmaceutical Trade Data And Forecasts (USDmn)
25
El Salvador
25
Table: El Salvador Pharmaceutical Trade Data And Forecasts (USDmn)
25
Panama
25
Table: Panama Pharmaceutical Trade Data And Forecasts (USDmn)
26
Honduras
26
Table: Honduras Pharmaceutical Trade Data And Forecasts (USDmn)
26
Nicaragua
27
Table: Nicaragua Pharmaceutical Trade Data And Forecasts (USDmn)
27
Industry Risk Reward Index
28
Americas Risk/Reward Index
28
Central America Risk/Reward Index
35
Rewards
35
Risks
35
Regulatory Review
37
Intellectual Property Issues
37
Costa Rica
38
El Salvador
39
Honduras
39
Nicaragua
40
Guatemala
40
Market Overview
41
Healthcare Sector - Country Specific Updates
41
Guatemala
41
Costa Rica
41
El Salvador
44
Panama
45
Honduras
47
Nicaragua
47
Clinical Trials
48
Epidemiology
50
Competitive Landscape
52
Research Based-Industry
52
Generic Drugmakers
52
Company Profile
53
Ancalmo Internacional
53
Donovan Werke
55
Glossary
57
Methodology
59
Pharmaceutical Expenditure Forecast Model
59
Healthcare Expenditure Forecast Model
59
Notes On Methodology
60
Risk/Reward Index Methodology
61
Index Overview
62
Table: Pharmaceutical Risk/Reward Index Indicators
62
Indicator Weightings
63

The Central America Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Central America Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras, to test other views - a key input for successful budgeting and strategic business planning in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Panamanian, Guatemalan, Nicaraguan, Salvadoran, Costa Rican, Belizean, Honduran pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Panama, Guatemala, Nicaragua, El Salvador, Costa Rica, Belize, Honduras.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.